Jesús
San Miguel Izquierdo
Consultor Investigador
Charité
Berlín, AlemaniaPublikationen in Zusammenarbeit mit Forschern von Charité (7)
2023
2022
-
Corrigendum to “OAB-005: Update of safety and efficacy of Isatuximab short-duration fixed-volume infusion plus Bortezomib, Lenalidomide, and Dexamethasone combined therapy for NDMM ineligible/with no immediate intent for ASCT” [Clinical Lymphoma Myeloma and Leukemia 21 S2 (2021) S3-S4](S2152265021X00122)
Clinical Lymphoma, Myeloma and Leukemia
-
Managing hematological cancer patients during the COVID-19 pandemic: an ESMO-EHA Interdisciplinary Expert Consensus
ESMO Open, Vol. 7, Núm. 2
2013
-
Phase Ib study of panobinostat and bortezomib in relapsed or relapsed and refractory multiple myeloma
Journal of Clinical Oncology
2009
-
The use of bisphosphonates in multiple myeloma: Recommendations of an expert panel on behalf of the European Myeloma Network
Annals of Oncology, Vol. 20, Núm. 8, pp. 1303-1317
2008
-
Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma
Leukemia, Vol. 22, Núm. 2, pp. 414-423
2006
-
A practical update on the use of bortezomib in the management of multiple myeloma
Oncologist, Vol. 11, Núm. 1, pp. 51-61